Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center.

Saved in:
Bibliographic Details
Title: Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center.
Authors: Oran B; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center. boran@mdanderson.org., Thall P; Department of Biostatistics, The University of Texas MD Anderson Cancer Center., Alousi A; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center., Al-Atrash G; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center., Mehta R; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center., Marin D; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center., Kebriaei P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center., Popat U; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center., Bassett R; Department of Biostatistics, The University of Texas MD Anderson Cancer Center., Bashir Q; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center., Im J; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center., Olson A; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center., Jewell J; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center., Smallbone P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center., Shpall E; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center., Champlin R; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center.
Source: Haematologica [Haematologica] 2026 Jan 01; Vol. 111 (1), pp. 149-157. Date of Electronic Publication: 2025 Jul 24.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1592-8721
DOI:10.3324/haematol.2025.287628